Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms

June 26, 2014 updated by: Repros Therapeutics Inc.

A Phase III, Open Label, Randomized, Multicenter Study Evaluating the Safety and Efficacy of 25 mg and 50 mg Doses of Proellex to Assess Recurrence of Symptoms in the Treatment of Symptomatic Uterine Fibroids

Subjects with symptomatic uterine fibroids will be enrolled and will receive daily oral study medication for 4 months. This will be followed by a 6 month off-drug interval until there is a return of significant symptomatology. If they experience symptoms of a certain severity, the subject will enter a second 4 month treatment cycle and then a follow-up period.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

Subjects with documented symptomatic uterine fibroids will be enrolled in the study. Following screening, subjects will receive daily oral study medication and will be assessed monthly for a 4 month treatment cycle. This first cycle will be followed by an off-drug interval until there is a return of significant symptomatology. Subjects will be followed for up to six (6) months post-treatment. If their lack of symptoms does not qualify them for a second cycle of treatment, they will be discharged from the study. If they experience symptoms of a certain severity, the subject will enter a second 4 month treatment cycle and then a follow-up period.

Study Type

Interventional

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
      • Jundiaí, Brazil, 13209-000
        • Vox Femina
      • São Paulo, Brazil, 08270-070
        • Hospital Santa Marcelina
      • São Paulo, Brazil, 01416-000
        • Brazilmed
      • São Paulo, Brazil, 04015-001
        • Universidade Federal de São Paulo - UNIFESP
      • São Paulo, Brazil, 04039-901
        • Hospital dos Servidores Públicos de SP
      • São Paulo, Brazil, 04230 - 000
        • Hospital Heliopolis
    • Paraná.
      • Curitiba, Paraná., Brazil, 80030-220
        • Cepeme/Cerfahc
  • United States
    • California
      • San Diego, California, United States, 92103
        • Genesis Center for Clinical Research
    • Florida
      • Sarasota, Florida, United States, 34239
        • Physician Care Clinical Research, LLC
    • Georgia
      • Atlanta, Georgia, United States, 30342
        • Atlanta Women's Research Inst.
      • Decatur, Georgia, United States, 30034
        • Soapstone Center for Clinical Research
    • Louisiana
      • Marrero, Louisiana, United States, 70072
        • York Clinical Consulting
    • Michigan
      • Grand Rapids, Michigan, United States, 49503
        • Female Pelvic Medicine
    • North Carolina
      • Winston-Salem, North Carolina, United States, 27103
        • Hawthorne Medical Research, Inc.
      • Winston-Salem, North Carolina, United States, 27103
        • Lyndhurst Gynecologic Associates
    • Oregon
      • Eugene, Oregon, United States, 97408
        • Clinical Trials of America
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107-5127
        • Thomas Jefferson University - Jefferson Center for Women's Medical Specialties
    • Tennessee
      • Memphis, Tennessee, United States, 38119
        • Women's Care Center, PLC Research Memphis Associates
      • Nashville, Tennessee, United States, 37208
        • Meharry Medical College
    • Texas
      • Plano, Texas, United States, 75093
        • Willowbend Health & Wellness Associates

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • At least one uterine fibroid must be identifiable and measurable by Transvaginal Ultrasound (TVU)
  • Subject must have uterine fibroid-associated symptoms during the-screening visit
  • Subject has menstrual cycle lasting from 20 to 40 days
  • Other inclusion criteria may apply

Exclusion Criteria:

  • Post-menopausal women or women likely to become post-menopausal during the study
  • Subject with a significant organ abnormality or disease (based on the Investigator's judgment) that would in the opinion of the Investigator exclude the subject from participating
  • Subject with any medical condition that, in the opinion of the Investigator, is not compatible with study procedures or which would prevent the subject from starting or completing the study, or interfere with the subject participating in this study.
  • Subject who has had an acute illness within five days of study medication administration
  • Subject with endometrial thickness of ≥ 18 mm on screening ultrasound or historically
  • Subject with an abnormal screening endometrial biopsy including the presence of Endometrial Intraepithelial Neoplasia (EIN)
  • Subject with an abnormal DEXA scan with a diagnosis or indication of osteoporosis at screening

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 25 mg
25 mg Proellex
Drug: Proellex
One 25mg capsule taken orally once every day.
Other Names:
  • Telapristone acetate
Drug: Proellex
Two 25mg capsules Proellex (50mg) taken orally once every day
Other Names:
  • Telapristone acetate
Experimental: 50 mg
50 mg Proellex
Drug: Proellex
One 25mg capsule taken orally once every day.
Other Names:
  • Telapristone acetate
Drug: Proellex
Two 25mg capsules Proellex (50mg) taken orally once every day
Other Names:
  • Telapristone acetate

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
To evaluate the safety of 25 and 50 mg Proellex administered once daily for two treatment cycles
Time Frame: Four months each cycle
Four months each cycle

Secondary Outcome Measures

Outcome Measure
Time Frame
To evaluate the efficacy of two different doses of Proellex used for the treatment of symptomatic uterine fibroids
Time Frame: Two, 4 month cycles
Two, 4 month cycles

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Repros Therapeutics Inc.

Investigators

  • Study Director: Andre van As, MD, PhD, Repros Therapeutics Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted

March 31, 2009

First Submitted That Met QC Criteria

March 31, 2009

First Posted (Estimate)

April 2, 2009

Study Record Updates

Last Update Posted (Estimate)

June 27, 2014

Last Update Submitted That Met QC Criteria

June 26, 2014

Last Verified

June 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ZPU-306

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Uterine Fibroids

Clinical Trials on Proellex

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe